Tremor and Other Hyperkinetic Movements

Case Reports

Anti-GAD Antibody-associated Syndrome Presenting with Limb Myoclonus

Pedro Manzke1,2*, Talyta Grippe1,2, Georgia L. Tavares1, Lucas C. Leal1, Emmanuel Roze3,4, Emmanuelle Apartis3,5, Ronaldo Maciel Dias1, & André G. F. Ferreira1

1Department of Neurology, Instituto Hospital de Base do Distrito Federal, Brasília, BR, 2Medicine Department, Centro Universitário de Brasília UNICEUB, Brasília, BR, 3AP-HP, Department of Neurology, Pitié-Salpêtriàre Hospital, Paris, FR, 4Sorbonne Université, Faculté de Médecine, Institut du Cerveau et de la Moelle Epiniàre, Paris, FR, 5AP-HP, Department of Neurophysiology, Saint-Antoine Hospital, Paris, FR

Abstract

Background: The clinical spectrum of anti-glutamic acid decarboxylase (GAD) antibody-associated neurologic syndromes is expanding, with focal, generalized, and atypical forms.

Case Report: We describe a 59-year-old female showing continuous right lower limb myoclonus and mild encephalopathy. These symptoms started 2 weeks prior to evaluation. The patient had great improvement with intravenous steroids. An autoantibody panel was positive for anti-GAD.

Discussion: Various clinical manifestations, including myoclonus, may relate to anti-GAD antibodies. The treatment options available include symptomatic drugs, intravenous immunoglobulin, steroids, and other immunosuppressant agents.

Keywords: Anti-glutamic acid decarboxylase antibodies, stiff person syndrome, autoimmunity, myoclonus, epilepsy

Citation: Manzke P, Grippe T, Tavares GL, Leal LC, Roze E, Apartis E, et al. Anti-GAD antibody-associated syndrome presenting with limb myoclonus. Tremor Other Hyperkinet Mov. 2018; 8. doi:10.7916/D8NK4XVP

*To whom correspondence should be addressed. E-mail: pmanzke@gmail.com

Editor: Elan D. Louis, Yale University, USA,

Received: July 17, 2018 Accepted: October 1, 2018 Published: October 29, 2018

Copyright: © 2018 Manzke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the user to copy, distribute, and transmit the work provided that the original authors and source are credited; that no commercial use is made of the work; and that the work is not altered or transformed.

Funding: None.

Financial Disclosures: None.

Conflicts of Interest: The authors report no conflict of interest.

Ethics Statement: All patients that appear on video have provided written informed consent; authorization for the videotaping and for publication of the videotape was provided.

Introduction

We present a 59-year-old female with continuous involuntary movements of her right leg. Mild bradyphrenia was also present. The symptoms started 2 weeks prior to evaluation.

Case report

The patient had a diagnosis of epilepsy 5 years previously. The manifestations were different from the current right leg symptoms. During the seizures, she had clonic movements of the left hand, left cephalic version, with further generalization. The seizures were partially controlled with carbamazepine 800 mg/day (one seizure every 3 months). However, 1 month before she was admitted to hospital, she had four seizures within the same day, with full recovery on the following day.

The patient’s mild bradyphrenia consisted of slowness of thinking and impaired attention, characterized by the need to repeat the same command several times. Patient’s orientation in time and space was normal.

Physical examination at rest showed spontaneous, continuous, irregular, low amplitude, involuntary movements limited to the right leg, suggestive of myoclonic jerks (Video 1 – Segment 1). The jerks were restricted to the proximal and distal right lower limb. The amplitude and frequency of movements worsened with action but improved during sleep. Stimulus sensitivity was apparently absent, but difficult to assess because of the patient’s continuous jerks. Deep tendon reflexes were normal. Rapid dorsiflexion of the right foot did not induce or exacerbate the involuntary movement. There were no painful spasms, startle, fixed postures, axial, or limb stiffness. The movements did not improve with valproate 2,500 mg/day and diazepam 40 mg/day.

During the episode, the electromyography (EMG) recorded with needle electrodes showed spontaneous and synchronous activation of right vastus lateralis and biceps femoralis. The burst duration was 30 ms, at a frequency of about 8 Hz, suggestive of myoclonus, in accordance with clinical observation. Electroencephalography (EEG), performed two times during the myoclonic jerks, showed mild disorganization of background activity, with 8 Hz alpha waves, but no paroxysms or focal slow waves. Back-averaging was not performed due to technical issues. EEG was compatible with mild encephalopathy. Brain and spinal magnetic resonance imaging showed non-specific mild T2 hyperintensities in the deep cerebral white matter and mild vertebral degenerative changes, respectively. Right and left tibial nerve somatosensory evoked potential (SSEP) was normal. Cerebrospinal fluid (CSF) revealed 20 white cells/mm3, 70% lymphocytes, 14 mg/dL protein, and 61 mg/dL glucose. She had no infectious stigma, and herpes and CMV serology were negative, bacterial, fungal, and tuberculosis cultures were also negative. Whole-body positron emission tomography/computed tomography scan was normal. Serum and CSF autoantibody panel was positive for anti-glutamic acid decarboxylase 65 (anti-GAD) antibodies, with strong reactivity in a tissue-based assay and immunoblotting. Although this test can also be interpreted by a qualitative analysis, the quantitative measure would have been more reliable but was not available.1 Antibodies to NMDAR, LGI1, GABAR, GlyR, AMPAR, and CASPR2 were negative. The patient’s fasting blood glucose level was within normal limits.

Before the result of the autoantibody panel, the patient was pulsed with 5 g of intravenous methylprednisolone (1 g per day), with a great improvement in both motor and cognitive symptoms (Video 1 – Segment 2). Our diagnosis was steroid-responsive anti-GAD-related limb myoclonus.

Discussion

A similar case has previously been reported, but myoclonus was seen on both legs and there was no associated encephalopathic features.2 A “jerking stiff person syndrome” has already been described, but the patient had additional axial rigidity and stimulus-sensitive multifocal myoclonus.3 The myoclonus of the present case was characterized by brief (30 ms) duration, which indicates cortical myoclonus.

Cortical myoclonus may be either epileptic or non-epileptic. Continuous cortical epileptic myoclonus may reflect epilepsia partialis continua.4 However, SSEP was normal, which does not further support the hypothesis of cortical myoclonus.4,5 Spinal myoclonus might be another possible origin, as it is characterized by variable stimulus sensitivity, no SSEP enlarged responses, and no cortical spikes or sharp waves on EEG. EMG in spinal myoclonus commonly reveals synchronous activation of the affected muscle.6 However, the classical duration range of spinal bursts is 50–500 ms,6 mostly over 100 ms.5 Also, the typical frequency is in the low range of 0.5–3 Hz.6 By contrast, our patient’s burst duration was around 30 ms and the frequency was 8 Hz.

The patient’s previous epileptic syndrome could have been an anti-GAD-related epilepsy.2 This previous epilepsy, in association with EEG encephalopathy at the time of examination, along with EMG short-duration and high-frequency bursts (30 ms and 8 Hz), supports the hypothesis of cortical myoclonus. We think that a cortical origin of myoclonus was the most likely in our patient. However, the level of the myoclonus generator could not be definitely ascertained due to several technical limitations. Notably, jerk-locked back-averaging was not performed.

The patient’s first clinical presentation was responsive to anti-epileptic drugs (AEDs). The second, 5 years later, was resistant to AEDs, but steroid responsive. Differences in responsiveness may be attributed to different cortical foci.

The anti-GAD antibody is found in various neurological syndromes, including stiff person syndrome (SPS), stiff limb syndrome (SLS), progressive encephalomyelitis with rigidity and myoclonus (PERM), opsoclonus–myoclonus, cerebellar ataxia, and autoimmune epilepsy.7 SPS, SLS, and PERM are part of the stiff person spectrum disorders (SPSDs), a broad and expanding clinical spectrum.8 SPSD can be linked with various antibodies other than anti-GAD.8

Anti-GAD antibody-associated neurologic syndromes are not strongly associated with cancer. Comprehensive investigation for tumors is not usually indicated.6 However, a study from a large database of 121 patients with anti-GAD-related syndromes identified 15 (12%) patients with tumors, such as lung cancer and thymic neoplasms.6 The clinical presentations were not always those typically observed in anti-GAD antibodies, such as limbic encephalitis.6 Thus, the atypical features from the present case prompted screening for cancer.

The mild encephalopathy and associated pleocytosis may suggest a PERM-related disorder. However, classical features of PERM were missing, such as dysautonomia, prominent brainstem involvement, rigidity, and generalized myoclonus.8 The current case may belong to SPSDs. SPSDs comprise focal variants, atypical forms, and generalized phenotypes.10 SPSD is an expanding concept.10 However, there was no clinical stiffness or related neurophysiological findings. In our opinion, it is thus not appropriate to classify this case under the umbrella of SPSDs. Our final diagnosis was an anti-GAD antibody-associated neurologic syndrome presenting with limb myoclonus.

References

1. Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT, et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav 2018;80:331–336. doi: 10.1016/j.yebeh.2018.01.021

2. Velardo D, Nuara A, Martinelli V, Comi G, Fazio R. Anti-GAD antibody-positive myoclonic leg jerks. Neurol Sci 2015;36:647–648. doi: 10.1007/s10072-014-2058-0

3. Marsden CD. A patient with reflex myoclonus and muscle rigidity: “jerking stiff-man syndrome”. J Neurol Neurosurg Psychiatry 1980;43:1125–1131. doi: 10.1136/jnnp.43.12.1125

4. Apartis E, Vercueil L. To jerk or not to jerk: a clinical pathophysiology of myoclonus. Rev Neurol 2016;172:465–476. doi: 10.1016/j.neurol.2016.07.013

5. Tijssen MAJ. Myoclonus subtypes in tertiary referral center. Cortical myoclonus and functional jerks are common. Clin Neurophysiol 2017;128:23–259. doi: 10.1016/j.clinph.2016.10.093

6. Caviness JN. The clinical neurophysiology of myoclonus. In: Hallet M, editor. Handbook of clinical neurophysiology. New York: Elsevier; 2003. p 521–548. doi: 10.1016/S1567-4231(09)70180-7

7. Tohid H. Anti-glutamic acid decarboxylase antibody positive neurological syndromes. Neurosciences 2016;21:215–222. doi: 10.17712/nsj.2016.3.20150596

8. Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders - new insights. Curr Opin Neurol 2016;29:496–506. doi: 10.1097/WCO.0000000000000351

9. Graus F. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol 2015;72:874–81. doi: 10.1001/jamaneurol.2015.0749

10. Sarva H, Deik A, Ullah A, Severt WL. Clinical spectrum of stiff person syndrome: a review of recent reports. Tremor Other Hyperkinet Mov 2016;6. doi: 10.7916/D85M65GD

Video 1. Segment 1. Before Treatment. Spontaneous, continuous, irregular, brief, involuntary movements restricted to the right lower limb, suggestive of myoclonic jerks, that worsen in amplitude and frequency with action. There is no rigidity or stimulus sensitivity. Gait is impaired by the involuntary movements. Segment 2. After Treatment – 1-Month Follow-up. Intravenous methylprednisolone pulse therapy improved symptoms. Involuntary movements are no longer observed. Gait is markedly improved.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License.

The opinions expressed within this journal do not necessarily reflect those of Tremor, its staff, its advisory Boards, or affiliates, or those of Columbia University.